Skip to main content
OpenTrials

Clinical trial condition

Endometrial Serous Adenocarcinoma

Explore clinical trials studying Endometrial Serous Adenocarcinoma. Study availability and eligibility vary by location and protocol.

30 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Endometrial Serous Adenocarcinoma trial results

Completed

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT01935973

Conditions
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, +3 more
Locations
  • Hartford Hospital Hartford, Connecticut, United States
  • The Hospital of Central Connecticut New Britain, Connecticut, United States
  • Augusta University Medical Center Augusta, Georgia, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
View all 22 locations
View Trial Details
Completed

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

NCT00478426

Conditions
Endometrial Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, +5 more
Locations
  • Tower Cancer Research Foundation Beverly Hills, California, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
View all 29 locations
View Trial Details
Completed

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT01132820

Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, +2 more
Locations
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank, California, United States
  • Palo Alto Medical Foundation-Gynecologic Oncology Mountain View, California, United States
  • Hartford Hospital Hartford, Connecticut, United States
  • The Hospital of Central Connecticut New Britain, Connecticut, United States
View all 87 locations
View Trial Details
Completed

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

NCT01010126

Conditions
Adenocarcinoma, Adnexal Diseases, Adult Hepatocellular Carcinoma, +76 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Tower Cancer Research Foundation Beverly Hills, California, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles County-USC Medical Center Los Angeles, California, United States
View all 61 locations
View Trial Details
Completed

Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer

NCT01005329

Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, +9 more
Locations
  • Alta Bates Summit Medical Center-Herrick Campus Berkeley, California, United States
  • John Muir Medical Center-Walnut Creek Walnut Creek, California, United States
  • Penrose-Saint Francis Healthcare Colorado Springs, Colorado, United States
  • Poudre Valley Hospital Fort Collins, Colorado, United States
View all 41 locations
View Trial Details
Completed

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT01642082

Conditions
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, +6 more
Locations
  • UCSF Medical Center-Mount Zion San Francisco, California, United States
  • Beebe Medical Center Lewes, Delaware, United States
  • Christiana Care Health System-Christiana Hospital Newark, Delaware, United States
  • Florida Hospital Orlando Orlando, Florida, United States
View all 30 locations
View Trial Details
Completed

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

NCT01210222

Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, +21 more
Locations
  • Hartford Hospital Hartford, Connecticut, United States
  • The Hospital of Central Connecticut New Britain, Connecticut, United States
  • Sarasota Memorial Hospital Sarasota, Florida, United States
  • Memorial University Medical Center Savannah, Georgia, United States
View all 33 locations
View Trial Details
Completed

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT00888173

Conditions
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, +6 more
Locations
  • University of Colorado Cancer Center - Anschutz Cancer Pavilion Aurora, Colorado, United States
  • The Hospital of Central Connecticut New Britain, Connecticut, United States
  • Rush University Medical Center Chicago, Illinois, United States
  • Saint Vincent Hospital and Health Care Center Indianapolis, Indiana, United States
View all 35 locations
View Trial Details
Completed

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT01225887

Conditions
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, +6 more
Locations
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank, California, United States
  • University of Colorado Cancer Center - Anschutz Cancer Pavilion Aurora, Colorado, United States
  • Smilow Cancer Hospital Care Center at Saint Francis Hartford, Connecticut, United States
  • Memorial University Medical Center Savannah, Georgia, United States
View all 59 locations
View Trial Details

Related conditions